In this video, the first in a 6-part series, panelists discuss the impact of monoclonal antibodies for COPD management.
Back
RX Review: Monoclonal Antibodies for COPD Management
A trio of experts in pulmonology discuss the role of monoclonal antibodies in the management of chronic obstructive pulmonary disease following the FDA approval of mepolizumab (Nucala).
RX Review: Monoclonal Antibodies for COPD Management
Episodes
All
All
In this video, the second in a 6-part series, panelists discuss using monoclonal antibodies in early-line COPD treatment.
In this video, the third in a 6-part series, panelists discuss how learnings from asthma management are informing COPD management.
In this video, the fourth in a 6-part series, panelists discuss how future studies of monoclonal antibodies in COPD could be refined.
In this video, the fifth in a 6-part series, panelists discuss the factors that influence initiating biologics for COPD.
In this video, the last in a 6-part series, panelists discuss the potential future impact of biologics in the COPD field.
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
The HCPFive: Top News for Healthcare Providers from the Week of 08/16
3
Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety
4
How a Physician With Crohn's Disease Approaches IBD Care
5